2 August 2024 - A groundbreaking pan-tumour pharmaceutical that can act upon multiple different tumour types has been publicly funded in Australia and is set to offer hope to thousands of patients who would otherwise likely die.

Vitrakvi is a highly effective treatment for advanced non-small cell lung cancer, soft tissue sarcomas and brain tumours that have a common genetic cause. It can treat cancers with a common genetic feature regardless of the type of cancer or where it is found in the body.

Read The Australian article